目的 探讨风湿祛痛胶囊联合柳氮磺吡啶肠溶片治疗强直性脊柱炎的临床疗效。方法 选取2018年11月-2020年1月郑州大学第一附属医院收治的90例强直性脊柱炎患者，将所有患者根据数字表法随机分为对照组和治疗组，每组各45例。对照组口服柳氮磺吡啶肠溶片，第1周为2片/次，第2周为3片/次，第3周为4片/次，均为2次/d。治疗组在对照组的基础上口服风湿祛痛胶囊，5粒/次，3次/d。两组患者均治疗8周。观察两组患者临床疗效，比较两组的巴氏强直性脊柱炎活动指数（BASDAI）评分、视觉模拟评分法（VAS）评分、巴氏强直性脊柱炎功能指数（BASFI）评分以及血清炎症因子水平。结果 治疗后，治疗组的总有效率88.89%高于对照组68.89%（P<0.05）。治疗后，两组巴氏强直性脊柱炎活动指数（BASDAI）、巴氏强直性脊柱炎功能指数（BASFI）、VAS评分均较治疗前下降（P<0.05），且治疗组BASDAI、BASFI、VAS评分低于对照组（P<0.05）。治疗后，两组血清C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）水平均显著下降（P<0.05），且治疗组血清CRP、TNF-α、IL-1β水平低于对照组（P<0.05）。结论 风湿祛痛胶囊联合柳氮磺吡啶肠溶片治疗强直性脊柱炎具有较好的临床疗效，可有效改善患者临床症状，降低CRP、TNF-α、IL-1β水平。

Objective To investigate the clinical effect of Fengshi Qutong Capsules combined with Sulfasalazine Enteric-coated Tablets in treatment of ankylosing spondylitis. Methods Patients (90 cases) with ankylosing spondylitis in the First Affiliated Hospital of Zhengzhou University from November 2018 to January 2020 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 2 tablets/time in the first week, three tablets/time in the second week, and four tablets/time in the third week, twice daily. Patients in the treatment group were po administered with Fengshi Qutong Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and BASDAI score, VAS score, BASFI score, and the serum levels of inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group (88.89%) was higher than that of the control group (68.89%) (P<0.05). After treatment, the scores of BASDAI, BASFI, and VAS in two groups were lower than those before treatment (P<0.05), and the scores of BASDAI, BASFI, and VAS in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of CRP, TNF-α, and IL-1β in two groups were significantly decreased (P<0.05), and the levels of CRP, TNF-α, and IL-1β in the treatment group were lower than those in the control group (P<0.05). Conclusion Fengshi Qutong Capsules combined with Sulfasalazine Enteric-coated Tablets has clinical curative effect in treatment of ankylosing spondylitis, can effectively improve the clinical symptoms, and reduce the levels of CRP, TNF-α, and IL-1β.

R977

河南省医学科技攻关计划项目（2017 T12128）